Figure 4.
A. Synthesized proof of concept HDAC degrader 4 and inhibitory activities against HDAC1, 2, 3, 6, and 8. B. HPLC‐chromatogram of the test cleavage of crude proof of concept PROTAC 4 (cleavage mix: 5 % TFA in CH2Cl2, 1 h, r.t.). C. Immunoblot analysis of cell lysate after HL‐60 cells were treated with 4 at various concentrations (0.1 μM, 1 μM and 10 μM).